BioRestorative Therapies Reports Promising Phase 2 Trial Results for Chronic Pain Treatment

BioRestorative Therapies, a leader in regenerative medicine, has recently shared encouraging results from its phase 2 clinical trial of BRTX-100, a groundbreaking treatment for chronic lumbar disc disease (cLDD). According to CEO Lance Alstodt, the trial demonstrated that over 74% of participants experienced more than a 50% improvement in function, with over 72% reporting a similar reduction in pain levels. These results not only surpass the FDA's clinically meaningful threshold of 30% but also highlight the potential of BRTX-100 to address the root cause of chronic pain, unlike traditional treatments that merely mask symptoms.

BRTX-100 utilizes a patient's own stem cells, which are harvested, cultured, and then injected directly into the affected disc to initiate the healing process. This autologous approach represents a significant advancement in the treatment of chronic lower back pain, offering hope to millions suffering from this debilitating condition. With the phase 2 trial on track to enroll 99 patients, the company is optimistic about the future, including the possibility of a pivotal trial or even an accelerated path to FDA approval.

During a recent interview with Benzinga, Alstodt also discussed BioRestorative's expansion plans and the broader implications of their work. The success of BRTX-100 could revolutionize the treatment of chronic pain, reducing reliance on opioids and other symptomatic treatments. For more details on this innovative therapy and its potential impact, watch the full interview here.